Magic Leap announced Tuesday that it was giving four healthcare partners early access to its next-gen augmented reality headset, including neurotechnology company SyncThink. With the new partnership, the company is interested in targeting vestibular disorders, which cause dizziness, SyncThink chief clinical officer Scott Anderson told The Verge.
SyncThink has been collaborating with Magic Leap for a few years, Anderson says. Now, it’s expanding that relationship to bring Magic Leap 2 into the neurological health space and collaborate on clinical studies, he says. SyncThink already has FDA clearance for an eye-tracking VR device that helps diagnose concussions. Changes in eye movements are also linked to vestibular disorders.